Schonfeld Strategic Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50,000	Closed	-$798K	–	2332
2024 Q3	$798K	Buy	+50,000	New	+$781K	0.01%	1237
2022 Q4	–	Sell	-510	Closed	-$25K	–	2946
2022 Q3	$25K	Buy	+510	New	+$28K	﹤0.01%	2703
2020 Q3	–	Sell	-1,683	Closed	-$143K	–	1606
2020 Q2	$143K	Buy	+1,683	New	+$153K	﹤0.01%	1146
2020 Q1	–	Sell	-607	Closed	-$43K	–	1461
2019 Q4	$43K	Buy	+607	New	+$29.3K	﹤0.01%	1233
2018 Q4	–	Sell	-2,000	Closed	-$933K	–	1213
2018 Q3	$933K	Buy	+2,000	New	+$804K	0.04%	441
2016 Q3	–	Sell	-1,562	Closed	-$656K	–	522
2016 Q2	$656K	Buy	+1,562	New	+$656K	0.15%	190

Other funds holding RNAC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schonfeld Strategic Advisors's RNAC Position: Q4 2024 in Review

Schonfeld Strategic Advisors sold out of Cartesian Therapeutics (RNAC) in Q4 2024, closing a stake of 50,000 shares — an estimated $798K sold.

Schonfeld Strategic Advisors first reported a position in RNAC in Q2 2016 and held it in 6 quarters. The position peaked at $933K in Q3 2018. 68 funds tracked by Wall St. Rank hold RNAC as of Q4 2024.

Schonfeld Strategic Advisors reported no remaining Cartesian Therapeutics position as of Q4 2024 after selling out during the quarter.
Schonfeld Strategic Advisors sold 50,000 Cartesian Therapeutics shares in Q4 2024, an estimated $798K.
Schonfeld Strategic Advisors first reported a position in Cartesian Therapeutics in Q2 2016 and held it in 6 quarters.
Schonfeld Strategic Advisors's Cartesian Therapeutics position peaked at $933K in Q3 2018.
68 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.